The U.S. Food and Drug Administration FDA has issued its yearly list of planned draft and final guidance documents for 2012. There are about 50 such guidance documents planned.
This is an overview about some important ones:
Biopharmaceutics and Biosimilarity:
Scientific Considerations in Demonstrating Biosimilarity To a Reference Product
Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product
Combination Products:
Development of Drugs in Combination
cGMPs and Compliance:
Control of Highly Potent Compounds
Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
Labeling, Packaging and Supply Chain:
Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling